ERR2598283
fetal · fetal
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- fetal
- cancer_type_detailed
- —
- subtype
- fetal
- cancer_type
- fetal
- subtype
- fetal
- sex
- fetal
- race
- fetal
- fetal_age_hindbrain
- 25
- umap1_2d
- -4.586063788
- umap2_2d
- -3.859138855
- umap1_3d
- 3.990132304
- umap2_3d
- 1.663583519
- umap3_3d
- -0.724682931
- dataset
- fetal
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-OR-A5L5-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.897 |
| 2 | SJEPD031138_D2.RNA-Seq | EPN | Supratentorial EPN | 0.889 |
| 3 | ERR2598341 | fetal | fetal | 0.888 |
| 4 | ERR2598329 | fetal | fetal | 0.875 |
| 5 | MDT-AP-2055 | Med | Medulloblastoma | 0.872 |
| 6 | ERR2598268 | fetal | fetal | 0.869 |
| 7 | ERR2598328 | fetal | fetal | 0.867 |
| 8 | TCGA-DQ-5630-01A-01R-1873-07 | — | — | 0.863 |
| 9 | BS_ARBQDTT5 | pilocytic astrocytoma | — | 0.860 |
| 10 | SRR1435753 | GTEX | — | 0.859 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.520 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.490 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.440 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.380 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.360 | Inavolisib | — uncovered |
| COMPLEMENT | 0.350 | Inavolisib | — uncovered |
| COAGULATION | 0.300 | Binimetinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.290 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.270 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.260 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.250 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.250 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.240 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.230 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.210 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.200 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.200 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.190 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.150 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.150 | Inavolisib | — uncovered |